Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Impact · against what's priced in

The all-stock merger of equals between Supernus and Indivior is a major catalyst, specifically for Indivior shareholders who will receive a $1.0 billion special cash dividend. While the combined entity gains scale and $125 million in cost synergies, the addition of $650 million in new debt to fund the dividend introduces moderate financial risk.

INDV+0.80

No priced-in read yet